Log In Or Register For Full Access
 Forgot username or password?
Not Registered?
Leaving This Site
You are now leaving GSKSource.
Please note that links to non-GSK sites are provided as a courtesy to GSKSource users, but that GSK is not responsible for the content found therein.
GSK Employee Access
GlaxoSmithKline employees must use their GSK laptop/desktop and must be logged into the GSK network to access this site.
If you are logged into the GSK network, please select continue to access the site.
Important Notice
This site is intended for US Healthcare Professionals. By clicking continue, you are acknowledging that you are a US Healthcare Professional.
(vardenafil hydrochloride) orally disintegrating tablets
Product Overview

Proven Efficacy Delivered in a Unique Way [1,2,3]

STAXYN is indicated for the treatment of erectile dysfunction.

Important Safety Information

  • Administration of STAXYN with nitrates and nitric oxide donors is contraindicated. Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors, including STAXYN, may potentiate the hypotensive effects of nitrates
  • The maximum dosing frequency is one tablet of STAXYN per day
  • STAXYN is not interchangeable with vardenafil 10-mg film-coated tablets (LEVITRA® [vardenafil HCl]). STAXYN provides higher systemic exposure compared to vardenafil 10-mg film-coated tablets (LEVITRA)
  • Treatment for ED, including STAXYN, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status
  • The use of STAXYN offers no protection against sexually transmitted diseases. Counseling of patients about protective measures necessary to guard against sexually transmitted diseases, including the Human Immunodeficiency Virus (HIV), should be considered
  • The evaluation of erectile dysfunction should include a medical assessment, a determination of potential underlying causes, and the identification of appropriate treatment
  • There have been rare reports of prolonged erections greater than 4 hours and priapism for this class of compounds, including vardenafil. In the event that an erection persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result
  • STAXYN should be used with caution by patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie's disease) or by patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia)
  • Do not use STAXYN with moderate and potent CYP3A4 inhibitors such as erythromycin, grapefruit juice, clarithromycin, ketoconazole, itraconazole, indinavir, saquinavir, atazanavir, and ritonavir as the systemic concentration of vardenafil is increased in their presence
  • Physicians should advise patients to stop use of all PDE5 inhibitors, including STAXYN, and seek medical attention in the event of sudden loss of vision in one or both eyes. Such an event may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, that has been reported rarely postmarketing in temporal association with the use of all PDE5 inhibitors. Physicians should also discuss with patients the increased risk of NAION in individuals who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators such as PDE5 inhibitors. STAXYN should be used with caution, and only when the anticipated benefits outweigh the risks, in patients with a history of NAION. Patients with a "crowded" optic disc may also be at an increased risk of NAION
  • Physicians should advise patients to stop taking all PDE5 inhibitors, including STAXYN, and seek prompt medical attention in the event of sudden decrease or loss of hearing. These events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the intake of PDE5 inhibitors, including vardenafil
  • In patients taking alpha-blockers, do not initiate vardenafil therapy with STAXYN. Patients treated with alpha-blockers who have previously used vardenafil film-coated tablets may be changed to STAXYN at the advice of their healthcare provider. Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. In some patients, concomitant use of these two drug classes can lower blood pressure significantly, leading to symptomatic hypotension
  • Patients taking Class 1A (for example, quinidine, procainamide) or Class III (for example, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation should avoid using STAXYN
  • Each tablet of STAXYN contains 1.01 mg phenylalanine per tablet, which could be harmful for patients with phenylketonuria
  • In placebo-controlled clinical trials, the most common adverse events reported by patients were headache (14.4%, 1.8%), flushing (7.6%, 0.6%), nasal congestion (3.1%, 0.3%), dyspepsia (2.8%, 0%), dizziness (2.3%, 0%) and back pain (2%, 0.3%) with STAXYN 10 mg and placebo, respectively
  • Do not use STAXYN in patients with moderate or severe hepatic impairment
  • Do not use STAXYN in patients on renal dialysis

Before prescribing STAXYN, please read the complete Prescribing Information.

Proven Efficacy...

  • Men taking STAXYN were twice as likely to maintain an erection long enough to have successful intercourse vs placebo (SEP3: 65% vs 26% for placebo; change from baseline: 51.6% vs 11.6% for placebo; P<0.0001) *[1]
  • SEP2: 74% response rate for STAXYN vs 45%; change from baseline: 35.9% vs 6.9% for placebo; P<0.0001 [1]
  • IIEF-EF domain score: 21 for STAXYN vs 14; change from baseline: 8.7 vs 1.6 for placebo; P<0.0001 [1]

...Delivered in a Unique Way

  • The first and only orally disintegrating PDE5 inhibitor [1]
  • Sleek and understated 4-tablet pack [1]

...and Priced With the Patient in Mind

To help ensure your patients get the unique sliding pack,
prescribe STAXYN in increments of 4 tablets [1]

*Sexual Encounter Profile Question 3 (SEP3): "Did your erection last long enough to have successful intercourse?"

†Sexual Encounter Profile Question 2 (SEP2): "Were you able to insert your penis into your partner's vagina?"

‡International index of Erectile Function - Erectile Function Domain (IIEF–EF).

Required Information

A state licence number is required to be on file for the state in which samples will be delivered
State Licence Number Licensing State